Press "Enter" to skip to content

ENTOD Pharmaceuticals eyes sale of more than half a million strips of Macushield Tablets in 2022

Macushield Tablets assist with Age-Related Macular Degeneration, Diabetic Retinopathy and Improves Overall Vision
Pharma Team, New Delhi:

India has around 77 million people above the age of 60 years representing a large section of the population vulnerable to vision-related disorders, and the number is estimated to reach 180 million by 2026. As per studies, the prevalence of Age-Related Macular Degeneration (AMD) in India ranges from 39.5% to 0.3%. The Union Health Ministry’s first National Diabetes and Diabetic Retinopathy Survey (2015-19) has also revealed that the prevalence of diabetic retinopathy is 16.9 per cent. AMD doesn’t cause complete blindness however, losing the central vision can make it harder to see faces, read, drive, or do close-up work. On the other hand, diabetic retinopathy at first might cause no symptoms or only mild vision problems. But it can lead to blindness.

Macushield is a specialized ocular supplement used in age-related macular degeneration (AMD) & diabetic retinopathy and can help improve overall eyesight. It is manufactured from 100% natural vegetarian sources (Bilberry extract, Pine Bark extract, Lutein, Zeaxanthin, etc.) consisting of potent macular pigments, essential vitamins & minerals to protect the macula from oxidative damage. The Macushield formula has been found to be a safer and more effective ocular supplement of choice for the management of AMD and diabetic retinopathy. So far the market response has been greatly encouraging with excellent feedback from both patients and prescribing eye specialists. This product has seen exponential growth over the years both in the domestic & overseas international markets. We expect the sale of Macushield to sky rocket in 2022 owing to a growing awareness of eye health and preventable blindness in the public” said Mr. Nikkhil K Masurkar, Executive Director of ENTOD Pharmaceuticals.
“Age-related macular degeneration occurs mostly in those older than 55, where it progressively damages the central portion of the retina, or macula, which is responsible for the sharpest vision. Macushield tablets can be easily swallowed, are capable of stopping the destruction, and can effectively transform the leading cause of blindness among people into a chronic but controllable medical condition. It is very well accepted by ophthalmologists around the country and worldwide, helping in vision & eyesight improvement. Composed of effective lipid soluble antioxidants and antioxidant enzymes, the relatively small size of the tablet makes it easier to swallow, thereby making it suitable and appropriate for older patients as well. Taking Macushield regularly as prescribed by your eye specialist can help to stop AMD and proliferative diabetic retinopathy in their tracks” said Mrs. Anjula Masurkar, Clinical Director of ENTOD Pharmaceuticals.

Be First to Comment

Leave a Reply

Your email address will not be published.